Underactive Bladder
Underactive bladder (UAB) is the symptom-based syndrome of impaired bladder emptying: weak stream, hesitancy, straining, prolonged voiding, incomplete emptying, and elevated post-void residual. Detrusor underactivity (DU) is the urodynamic diagnosis: a detrusor contraction of reduced strength and/or duration, causing prolonged emptying or failure to empty completely within a normal time span.[1][2]
The distinction matters. Patients describe UAB; urodynamics proves DU. Low flow alone does not distinguish DU from bladder outlet obstruction (BOO), and many patients have both.
Terminology
| Term | Meaning | Practical use |
|---|---|---|
| Underactive bladder (UAB) | Symptom complex associated with impaired emptying | Clinical syndrome; analogous to OAB |
| Detrusor underactivity (DU) | Urodynamic diagnosis of weak and/or short detrusor contraction | Requires pressure-flow testing |
| Acontractile detrusor (ACD) | No demonstrable detrusor contraction on urodynamics | Worst contractility phenotype; catheter dependence more likely |
| Impaired detrusor contractility | Reduced detrusor strength, speed, or persistence | Broader physiologic concept |
| DHIC | Detrusor hyperactivity with impaired contractility | Storage overactivity plus poor emptying |
DU is not synonymous with retention. A patient can void with low efficiency, empty by abdominal straining, or have apparently acceptable PVR early in the disease.
Epidemiology
True prevalence is unknown because most data come from referral cohorts undergoing urodynamics.[1][3]
Approximate ranges in urodynamic series:
- Men with non-neurogenic LUTS: 9-48%
- Older women with non-neurogenic LUTS: 12-45%
- Women with pelvic floor disorders: 4-37%, depending on the definition used
- Institutionalized older adults with incontinence: DU and DHIC are common contributors
Prevalence is definition-sensitive. A strict pressure-flow index captures a different population than a voiding-efficiency definition, and many published thresholds were derived in men before being applied to women.
Pathophysiology
DU is a final common pathway, not a single disease.
Myogenic failure
- Loss of detrusor smooth muscle cells
- Collagen deposition and fibrosis
- Impaired excitation-contraction coupling
- Reduced contraction speed, duration, and reserve power
Neurogenic failure
- Sacral / cauda equina lesions
- Peripheral neuropathy, especially diabetes
- Pelvic autonomic nerve injury after radical pelvic surgery
- Spinal cord disease, multiple sclerosis, stroke, Parkinson disease, and other NLUTD phenotypes
- Impaired afferent sensation: bladder fills but the patient does not generate an adequate voiding reflex
Vascular and metabolic injury
Microvascular disease, diabetes, aging, and cardiovascular disease may reduce detrusor blood supply and impair neural and muscular reserve.[4]
BOO-related decompensation
Chronic obstruction produces bladder remodeling:
- Hypertrophy — the detrusor works against higher outlet resistance.
- Compensation — voiding pressure rises; filling-phase detrusor overactivity may appear.
- Decompensation — contractility fails, PVR rises, and DU develops.[5]
This is why outlet surgery can help some men with DU: removing obstruction may let a weak but still viable detrusor empty better. It will not rescue an acontractile, insensate bladder reliably.
Risk Factors and Etiology
| Category | Examples |
|---|---|
| Age-related | Detrusor muscle aging, sensory decline, comorbidity accumulation |
| Metabolic / vascular | Diabetes, metabolic syndrome, cardiovascular disease, microvascular disease |
| Neurogenic | Spinal cord injury, cauda equina syndrome, multiple sclerosis, stroke, Parkinson disease, peripheral neuropathy |
| Iatrogenic | Radical pelvic surgery, hysterectomy, rectal surgery, pelvic radiation, medications |
| Outlet-related | Chronic BPH/BPO, urethral stricture, bladder neck contracture, dysfunctional voiding |
| Medication-related | Anticholinergics, opioids, antihistamines, sympathomimetics, tricyclics, some antipsychotics |
In practice, the most common patient is mixed: older, diabetic or vascular, exposed to anticholinergic medications, with some degree of outlet obstruction or pelvic-floor dysfunction.
Clinical Presentation
Voiding symptoms
- Weak stream
- Hesitancy
- Intermittency
- Straining
- Prolonged voiding time
- Terminal dribbling
- Need to double void
Post-micturition symptoms
- Incomplete emptying
- Post-void dribbling
- Early return of urge after voiding
Storage symptoms
- Frequency
- Nocturia
- Urgency
- Urgency incontinence
Storage symptoms can reflect DHIC, chronic retention, recurrent infection, high residual volumes, or coexisting OAB.
Signs
- Elevated PVR
- Palpable bladder
- Overflow incontinence
- Recurrent UTI
- Reduced or absent bladder sensation
- Hydronephrosis in severe chronic retention
DU vs BOO
Symptoms overlap heavily. The reconstructive trap is assuming that every weak stream is obstruction or that every low-flow tracing is DU.
| Feature | More suggestive of DU | More suggestive of BOO |
|---|---|---|
| Sensation | Reduced filling sensation, delayed first desire | Normal sensation, urgency from obstruction |
| Flow | Low flow with low detrusor pressure | Low flow with high detrusor pressure |
| PVR | Often high, may be very high | Variable; rises with decompensation |
| Prostate / urethra | Small prostate or no clear anatomic narrowing | BPH, stricture, bladder neck contracture, sling obstruction |
| Urodynamics | Low Pdet@Qmax, low voiding efficiency | High pressure-low flow |
Pressure-flow urodynamics is the decisive test when the diagnosis will change treatment.
DHIC
Detrusor hyperactivity with impaired contractility (DHIC) is the combination of detrusor overactivity during filling and impaired contractility during voiding. It is common in frail older adults and may present as incontinence, urgency, recurrent cystitis, retention, or both.[6]
The management problem is obvious: OAB drugs may worsen emptying, while cholinergic drugs do not reliably improve emptying. Treatment usually prioritizes safe emptying first, then storage control.
Practical sequence:
- Measure PVR before starting antimuscarinic or botulinum therapy.
- Treat infection, constipation, and medication contributors.
- Establish reliable emptying if PVR is high: CIC, caregiver catheterization, or suprapubic tube.
- Add storage therapy cautiously: beta-3 agonist, low-burden antimuscarinic, or botulinum only if catheterization is feasible.
Evaluation
Initial assessment
- LUTS history: voiding, storage, post-micturition, duration, bother
- Retention history: acute retention, catheter episodes, failed void trials
- Neurologic history: spine disease, diabetes, stroke, MS, Parkinson disease, pelvic surgery
- Medication review
- Bowel function and constipation
- Pelvic / prostate / neurologic exam
- Urinalysis and urine culture when symptomatic
- PVR measurement, repeated if unexpectedly high
- Uroflowmetry
- Voiding diary when frequency/nocturia is prominent
Urodynamics
Urodynamics is required for a definitive diagnosis of DU.[1][7]
Typical findings:
- Low Qmax
- Low Pdet@Qmax
- Slowly rising or brief detrusor contraction
- Intermittent or unsustained contraction
- Large PVR
- Low voiding efficiency
- Reduced bladder sensation
- Abdominal straining during voiding
Contractility metrics
No single criterion is universally accepted.
| Metric | Formula / concept | Use |
|---|---|---|
| BCI | Pdet@Qmax + 5 x Qmax | Common in men; low values suggest impaired contractility |
| Voiding efficiency | Voided volume / bladder capacity | Simple functional endpoint; useful across sexes |
| Pdet@Qmax | Detrusor pressure at maximum flow | Separates low-pressure-low-flow from high-pressure-low-flow |
| Video-UDS | Pressure-flow plus fluoroscopy | Best for mixed DU/BOO, bladder neck dysfunction, sphincter non-relaxation |
When to obtain video-urodynamics
- Prior outlet surgery or pelvic reconstruction
- Suspected BOO plus weak detrusor
- Neurogenic disease
- Elevated PVR before continence surgery
- Women with suspected sling obstruction or dysfunctional voiding
- Men with small prostate and severe low-flow symptoms
- Failed outlet surgery or unexpected postoperative retention
Management Principles
The goals are:
- Prevent overdistension, UTI, stones, hydronephrosis, and renal injury.
- Make bladder emptying reliable.
- Treat storage symptoms without worsening retention.
- Avoid unnecessary outlet surgery in acontractile or insensate bladders.
Conservative and Drainage Management
Clean intermittent catheterization
Clean intermittent catheterization (CIC) is the preferred long-term drainage strategy when emptying is inadequate and the patient or caregiver can perform it.[8][9]
Advantages:
- Lower urethral erosion risk than indwelling catheter
- Lower stone and infection burden than chronic indwelling drainage in many patients
- Preserves sexual function and mobility better than urethral catheter
- Allows measured emptying schedule
Practical targets:
- Catheterize often enough to avoid painful distension and high residual volumes.
- Use hydrophilic or closed systems when recurrent trauma or UTI is an issue.
- Match plan to dexterity, cognition, caregiver support, and urethral anatomy.
Suprapubic catheter
Use when CIC is not feasible, urethral catheterization is traumatic, or long-term drainage is required. SPC is generally preferable to chronic urethral catheterization when a durable catheter route is needed.
Behavioral measures
- Timed voiding
- Double voiding
- Avoid bladder overdistension
- Treat constipation
- Reduce sedating and anticholinergic medication burden
- Avoid Valsalva voiding as the only plan in high-risk or obstructed patients
Valsalva voiding may empty an areflexic, low-resistance outlet, but it is a poor solution when outlet resistance is high, pelvic organ prolapse is present, or upper-tract risk exists.
Pharmacologic Therapy
Drug therapy for DU is disappointing.
| Treatment | Role | Caveat |
|---|---|---|
| Bethanechol / cholinergic agonists | Legacy therapy for detrusor atony | Limited efficacy, frequent adverse effects; rarely transformative[10] |
| Distigmine / anticholinesterase agents | Used in some regions | Side effects and limited evidence |
| Alpha blockers | Reduce bladder neck / prostatic smooth muscle tone | Useful when outlet resistance contributes; especially spontaneous voiders with NLUTD[9] |
| Alpha blocker + cholinergic agent | May improve flow/PVR more than either alone in selected patients | Evidence limited; monitor adverse effects[11] |
| Beta-3 agonists / antimuscarinics | Treat storage symptoms or DHIC | Check and monitor PVR; catheterization plan must be clear |
Medication works best when the problem is mixed DU plus functional outlet resistance, not a truly acontractile detrusor.
Sacral Neuromodulation
Sacral neuromodulation (SNM) is one of the few therapies with meaningful evidence for non-obstructive urinary retention and selected DU.[12][13]
Best candidates:
- Non-obstructive retention
- Preserved bladder sensation
- Some preserved contractility
- Younger patients
- No fixed anatomic obstruction
- Able to participate in trial-phase voiding diary and catheter-volume tracking
Less favorable:
- Acontractile detrusor
- Absent bladder sensation
- Severe chronic overdistension
- Advanced neurogenic disease with poor sacral reflex arc
- Uncorrected outlet obstruction
Published series report roughly half of DU patients responding to the test phase. Preserved contractility predicts better response; acontractile detrusor responds less reliably.[12]
Outlet-Directed Treatment
Outlet treatment can help a weak bladder if outlet resistance is meaningfully contributing.
Men
Consider outlet surgery when video-UDS or cystoscopy shows:
- BPH/BPO with obstruction
- Tight bladder neck
- Urethral stricture
- Bladder neck contracture
- Poor relaxation of external sphincter
In male DU cohorts, bladder outlet surgery can improve voiding efficiency, especially when detrusor contractility and bladder sensation are preserved.[14] Outcomes are worse when the detrusor is acontractile or sensation is absent.
Women
Look for:
- Prior sling obstruction
- Pelvic organ prolapse
- Fowler-type sphincter non-relaxation
- Dysfunctional voiding
- Urethral stricture
- Medication-induced retention
Sling incision or urethrolysis helps obstruction; it does not treat primary DU and may unmask stress incontinence.
Botulinum toxin to outlet
Urethral sphincter botulinum toxin may help selected patients with poor sphincter relaxation, DSD, or functional outlet obstruction. It is not a detrusor-strengthening therapy.
Reconstructive Decision Points
- Before SUI surgery: measure PVR and consider urodynamics when symptoms suggest impaired emptying. A sling or AUS in an underactive bladder can convert borderline emptying into retention.
- Before BPH surgery: distinguish BOO from DU. If both are present, counsel that surgery may improve emptying but urgency, weak stream, or catheter need may persist.
- Before botulinum for OAB: confirm the patient can catheterize if retention worsens.
- Before urinary diversion or bladder neck closure: establish whether the issue is unsafe storage, unsafe emptying, outlet incompetence, or patient-care logistics.
- After pelvic surgery: new retention can be neuropraxia, pain/opioids, hematoma, sling obstruction, or true denervation. Do not label permanent DU too early.
Prognosis
Better prognosis:
- Preserved bladder sensation
- Some measurable detrusor contraction
- Treatable outlet resistance
- Shorter duration of retention
- Lower baseline PVR
- Ability to perform CIC during recovery
Worse prognosis:
- Acontractile detrusor
- Absent bladder sensation
- Severe chronic overdistension
- Advanced diabetes or neurologic disease
- Long-standing retention with recurrent infection, stones, or hydronephrosis
Complications of untreated DU include recurrent UTI, acute retention, overflow incontinence, bladder stones, upper-tract dilation, and renal deterioration.
See Also
- Urodynamics
- Benign Prostatic Hyperplasia
- Bladder Neck Contracture
- Urethral Stricture
- Neurogenic Lower Urinary Tract Dysfunction
- Alpha Blockers
- Cholinergic Agonists
References
1. Osman NI, Chapple CR, Abrams P, et al. "Detrusor Underactivity and the Underactive Bladder: A New Clinical Entity? A Review of Current Terminology, Definitions, Epidemiology, Aetiology, and Diagnosis." Eur Urol. 2014;65(2):389-398. doi:10.1016/j.eururo.2013.10.015
2. Drake MJ, Williams J, Bijos DA. "Voiding Dysfunction Due to Detrusor Underactivity: An Overview." Nat Rev Urol. 2014;11(8):454-464. doi:10.1038/nrurol.2014.156
3. Osman NI, Esperto F, Chapple CR. "Detrusor Underactivity and the Underactive Bladder: A Systematic Review of Preclinical and Clinical Studies." Eur Urol. 2018;74(5):633-643. doi:10.1016/j.eururo.2018.07.037
4. Taylor JA, Kuchel GA. "Detrusor Underactivity: Clinical Features and Pathogenesis of an Underdiagnosed Geriatric Condition." J Am Geriatr Soc. 2006;54(12):1920-1932. doi:10.1111/j.1532-5415.2006.00917.x
5. Bosch R, Abrams P, Averbeck MA, et al. "Do Functional Changes Occur in the Bladder Due to Bladder Outlet Obstruction? - ICI-RS 2018." Neurourol Urodyn. 2019;38 Suppl 5:S56-S65. doi:10.1002/nau.24076
6. Resnick NM, Yalla SV. "Detrusor Hyperactivity With Impaired Contractile Function. An Unrecognized but Common Cause of Incontinence in Elderly Patients." JAMA. 1987;257(22):3076-3081. doi:10.1001/jama.257.22.3076
7. Gammie A, Kaper M, Dorrepaal C, Kos T, Abrams P. "Signs and Symptoms of Detrusor Underactivity: An Analysis of Clinical Presentation and Urodynamic Tests From a Large Group of Patients Undergoing Pressure Flow Studies." Eur Urol. 2016;69(2):361-369. doi:10.1016/j.eururo.2015.08.014
8. Dewulf K, Meurice A, Duvillier T, et al. "Detrusor Underactivity and Acontractile Bladder Patients Performing Clean Intermittent Catheterization in a Single Tertiary Referral Center: What Is Happening in Real Life?" Int Urogynecol J. 2025;36(7):1533-1540. doi:10.1007/s00192-025-06181-3
9. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-Up." J Urol. 2021;206(5):1106-1113. doi:10.1097/JU.0000000000002239
10. Gaitonde S, Malik RD, Christie AL, Zimmern PE. "Bethanechol: Is It Still Being Prescribed for Bladder Dysfunction in Women?" Int J Clin Pract. 2019;73(8):e13248. doi:10.1111/ijcp.13248
11. Yamanishi T, Yasuda K, Kamai T, et al. "Combination of a Cholinergic Drug and an Alpha-Blocker Is More Effective Than Monotherapy for the Treatment of Voiding Difficulty in Patients With Underactive Detrusor." Int J Urol. 2004;11(2):88-96. doi:10.1111/j.1442-2042.2004.00753.x
12. Chan G, Qu LG, Gani J. "Evaluation of Pre-Operative Bladder Contractility as a Predictor of Improved Response Rate to a Staged Trial of Sacral Neuromodulation in Patients With Detrusor Underactivity." World J Urol. 2021;39(6):2113-2119. doi:10.1007/s00345-020-03380-z
13. Onur R, Tayebi S, Salehi-Pourmehr H, et al. "Sacral Neuromodulation in Patients With Detrusor Underactivity: Is Biological Sex an Indicator?" Neurourol Urodyn. 2022;41(3):847-859. doi:10.1002/nau.24893
14. Lee CL, Jhang JF, Ho HC, et al. "Therapeutic Outcome of Active Management in Male Patients With Detrusor Underactivity Based on Clinical Diagnosis and Videourodynamic Classification." Sci Rep. 2022;12(1):362. doi:10.1038/s41598-021-04237-0